Introduction
Angiogenesis, the growth of new capillaries from preexisting one, is a multistep process that involves enzymatic degradation and remodelling of the extracellular matrix, migration and proliferation of capillary endothelial cells, tissue in®ltration and lumen formation (Cao et al., 1996; Breier and Risau, 1996) . The angiogenic process is required in many physiological and pathological conditions including embryonic development, wound healing, tissue regeneration and tumor growth (Folkman and Klagsbrun, 1987) . Recent studies indicate that vascular endothelial growth factor (VEGF) is a major regulator of both physiological and pathological angiogenesis (Breier and Risau, 1996) .
VEGF is an endothelial cell-speci®c mitogenic and chemotactic agent. It induces in endothelial cells the production of the plasminogen activators required for the proteolytic degradation of the extracellular matrix during sprouting of capillaries and it increases the vascular hyperpermeability that precedes new blood vessel formation (Hyder et al., 1996) . Within the human vascular cell wall, VEGF is produced by vascular smooth muscle cells and it modulates endothelial cell functions via a paracrine pathway (Brogi et al., 1994) . Alternatively, an autocrine loop involving the production of VEGF by human endothelial cells can be activated under speci®c conditions such as hypoxia (Namiki et al., 1995) . High expression of VEGF is found in various organs undergoing angiogenesis, including the female reproductive apparatus and the eyes of patients with diabetic retinopathy (Brogi et al., 1994) . VEGF is also produced by a variety of tumor cells and, thus, may contribute to tumor expansion associated with neovascularization. Interestingly, estrogens increase the uterine expression of VEGF which raises the possibility that VEGF contributes to tumor development in organ like uterus and breast which produced 17 b-estradiol (Hyder et al., 1996) . In non endothelial cells, VEGF regulates cell motility in monocytes, dierentiation in osteoclasts and production of insulin by pancreatic b cells (Class et al., 1990; Midy and Plouet, 1994; Oberg et al., 1994) .
VEGF exerts its eects after binding with two receptor-tyrosine-kinases, Flt-1 (VEGFR-1) and KDR/Flk-1 (VEGFR-2), present at the surface of endothelial cells (Mustonen and Alitalo, 1995; Soker et al., 1996) . The post-receptor signal transduction pathways which regulate the eects of VEGF in endothelial cells are still poorly understood. VEGF receptors utilize signal transduction pathways that involve the activation of Ras GTPase activating protein, phosphatidylinositol-3 kinase (PI3-K), and phospholipase Cg (PLCg) (Guo et al., 1995; Seetharam et al., 1995; Cunningham et al., 1995; Breier and Risau, 1996) . However, no clear association has been established, so far, between activation of these pathways and the angiogenic activity of VEGF. Members of the mitogen activated protein (MAP) kinase family, ERK (extracellular signal-regulated kinase), SAPK1/ JNK (stress activated protein kinase-1/c-Jun NH 2 -terminal kinase) and p38 (stress activated protein kinase-2), are central elements which transduce the signal generated by growth factors, cytokines and stressing agents (Waskiewicz and Cooper, 1995; Kyriakis and Avruch, 1996; Cuenda et al., 1997) . VEGF has been reported to activate ERK in capillary endothelial cells and rat liver sinusoidal endothelial cells (Seetharam et al., 1995; D'Angelo et al., 1995) . However, the role of ERK as well as that of the other MAP kinases in modulating the endothelial functions of VEGF remain unclear.
In the present study, we have investigated the role of the MAP kinases, ERK, SAPK1/JNK and p38 in mediating the VEGF-induced cell migration in vascular endothelial cells. We report that VEGF activates both ERK and p38 MAP kinases in primary cultures of human umbilical vein endothelial cells (HUVEC) and show that activation of ERK is associated with increased cell proliferation whereas p38 mediates actin organization and cell migration. We conclude that p38, by mediating cell migration, is an important modulator of the angiogenic eect of VEGF.
Results

Activation of cell migration by VEGF
The eect of VEGF on cell migration was assayed by measuring the trans®lter migration activity of HUVEC seeded on a gelatinized polycarbonate membranes separating the lower and upper part of Boyden modi®ed chambers. VEGF when added for 2 h in the lower chamber induced a strong activation of cell migration. Maximal activation was reached with 5 ng/ ml VEGF whereas higher concentrations of VEGF inhibit cell migration yielding the classical bell shape curve that characterized the expression of migration in relation with increasing concentrations of ligand ( Figure 1 ).
Activation of MAP kinases by VEGF
The activity of the three MAP kinases, ERK, SAPK1/ JNK and p38 was determined in HUVEC exposed for various periods of time to 5 ng/ml VEGF. This concentration of VEGF induced maximal activation of cell migration. Extracts were prepared from the cultures and the activities of the MAP kinases determined as described in Materials and methods. Results presented in Figure 2 show that VEGF induced a transient activation of both ERK and p38 which reached a peak of 5 ± 7-fold over basal level after 5 min. In contrast, VEGF did not activate SAPK1/ JNK that was, however, strongly activated by Il-1b Figure 1 Activation of cell migration by VEGF. HUVEC were plated on a gelatinized polycarbonate membrane (8 mm pore size) in a modi®ed Boyden chamber and were exposed for 120 min to varying concentrations of VEGF added to the lower chamber. BSA 1% was used as control. At the end of the treatments, cells on the lower part of the membranes were stained with Mayer's Hematoxilin and counted in ®ve dierent ®elds at 6100 magni®cation. Data points represent the mean number of migrating cells/®eld (+s.d) calculated in three dierent wells. Representative results from two separate experiments are shown Figure 2 Activation kinetics of the MAP kinases ERK2, p38 and SAPK1/JNK by VEGF. HUVEC were left untreated or were exposed for 3 ± 120 min to VEGF (5 ng/ml) or for 20 min to IL-1b (20 ng/ml) as a positive control. VEGF was added, as in all experiments, directly into the culture medium and the exposures did not involve medium changes. After treatments, extracts were prepared and processed for kinase assays in presence of [g 32 P]ATP. ERK2 (A) and p38 (B) activities were determined in immunocomplexes using MBP (myelin basic protein) and ATF2-GST as substrates respectively. In the case of SAPK1/JNK (C) activity, the cell extracts were adsorbed on GST-c-jun beads and the kinase activity was tested using the same GST-N-terminal Jun as substrate. Proteins were separated by SDS ± PAGE and kinase activities were visualized by autoradiography and were quanti®ed by measuring the incorporation of 32 P into the speci®c substrates. Results are expressed as the ratio of the kinase activities of stimulated cells over the activity of unstimulated cells. Representative results from two separate experiments are shown p38 MAP kinase regulates cell migration induced by VEGF S Rousseau et al (20 ng/ml; 20 min). The dose-response curve of VEGFinduced p38 activation, but not that of VEGF-induced ERK activation, followed a bell-shape pattern comparable to the pattern that characterized the dose-response curve of VEGF-induced increase of cell migration ( Figure 3 and Figure 1 ).
p38-dependent activation of cell migration by VEGF
As shown in Figures 4a and c, activation of ERK by VEGF was inhibited by pretreatment of the cells with PD098059 (IC 50 =10 mM) a selective inhibitor of the ERK activator, MEK1, whereas p38 activity was speci®cally blocked by SB203580 (IC 50 =0.3 mM) as evidenced by the inhibition of MAPKAP kinase-2/3, a speci®c downstream target of p38 (Rouse et al., 1994; McLaughlin et al., 1996; Guay et al., 1997; Huot et al., 1997) . VEGF also induced a SB203580-sensitive phosphorylation of HSP27, the physiological substrate of MAPKAP kinase-2/3 ( Figure 4e ). SB203580 at concentrations up to 25 mM (80-fold the IC 50 for inhibition of p38 activity) did not inhibit the activation of ERK by VEGF nor did PD098059, in concentrations which maximally blocked ERK activation, inhibit the stimulation of p38 activity by VEGF (Figure 4f ). In addition, neither inhibitors had modi®ed the responsiveness of JNK/SAPK1 to VEGF (data not shown). These observations are consistent with previous reports which showed the speci®city of SB203580 and PD098059 toward p38 and MEK1 respectively Dudley et al., 1995; Alessi et al., 1995; Huot et al., 1997) . The role of p38 and ERK in mediating stimulation of cell migration by VEGF was determined by examining the eect of SB203580 and PD098059 on the VEGF-induced cell migration. Increasing concentrations of the inhibitors were added in the upper and lower parts of Boyden modi®ed chambers 15 min before the addition of 5 ng/ml VEGF in the lower chamber. Migration of cells across the gelatinized polycarbonate membranes was then determined 2 h after the addition of VEGF. Results showed that SB203580 led to a dose dependent-inhibition of VEGFinduced cell migration ( Figure 4d ). The concentration of SB203580 which reduced by 50% the maximal activation of VEGF-induced cell migration was about 0.5 mM, a value similar to the IC 50 of the inhibitor against MAPKAP K2/3 activation by p38. At 5 mM, SB203580 inhibited by 80% the increased cell migration induced by VEGF. The results strongly suggest that p38 is implicated in transducing the VEGF signal which leads to cell migration. In contrast, inhibiting ERK activation with PD098059 had no eect on the stimulation of cell migration by VEGF (Figure 4b ). However, inhibition of ERK activation but not of p38 activity was incompatible with cell growth and inhibited the VEGF (5 ng/ml: 48 h)-induced twofold increase of [ 
p38-dependent stress ®ber formation induced by VEGF
Cell migration is associated with regulation of actin dynamics (Mitchison and Cramer, 1996) . Accordingly, we observed that cytochalasine D, an inhibitor of actin polymerization, totally inhibited cell migration in concentration as low as 0.1 mM (data not shown). It has been reported that VEGF disorganizes actin ®laments in Balb/c3T3 cells and produces edge ruffling in endothelial cells (Enomoto et al., 1994; Waltenberger et al., 1994) . However, these changes were obtained with high concentrations of VEGF (50 ± 100 ng/ml) that do not increase cell migration in HUVEC. We thus investigated here the eects of VEGF on actin Figure 3 Dose-response curves of VEGF-induced activation of p38 and ERK2. HUVEC were left untreated or were exposed for 5 min to varying concentrations of VEGF. Extracts were prepared and processed for ERK2 (A) and p38 (B) assays in immunocomplexes using MBP and ATF2-GST as substrates respectively. Proteins were separated by SDS ± PAGE and the kinase activities were quanti®ed by measuring the incorporation of Activation of cell migration by VEGF is p38-but not ERK-dependent. HUVEC were pre-treated for 15 min with the indicated increasing concentrations of PD098059 to inhibit ERK activation (A) or SB203580 to inhibit p38 activity (C) and thereafter were exposed for 5 min to VEGF (5 ng/ml). After treatments, extracts were prepared and processed for kinase assays in presence of [g 32 P]ATP. ERK2 (a) and MAPKAP kinase 2/3 (C) activities were determined in immunocomplexes using MBP and rHSP27 as substrates respectively. Proteins were separated by SDS ± PAGE and kinase activities were quanti®ed as in Figure 2 . Kinase activities are expressed as the ratio of the enzyme activity in the presence of the inhibitor added before VEGF over the activity in presence of VEGF alone. In (B) and (D), HUVEC plated on a gelatinized polycarbonate membrane (8 mm pore size) in a modi®ed Boyden chamber were pre-treated for 15 min with the indicated concentrations of PD098059 (B) or SB203580 (D) added to both the upper and lower chambers. VEGF (5 ng/ml) was then added for 2 h to the lower chamber. Each well contained the same concentration of the vehicle DMSO (0.25%). Cell migration was evaluated as in Figure 1 . Data points represent the mean number of migrating cells/®eld (+s.d.) calculated in three dierent wells. In (E) cells were preincubated for 2 h in phosphate free medium containing H 3 [ 32 P]O 4 and were then left untreated (lane 1) or were pretreated with SB203580 (1 mM, 15 min; lane 3) followed by VEGF (5 ng/ml, 15 min; lanes 2,3). After treatments, cells were lysed and proteins were fractionated by SDS ± PAGE. Incorporation of 32 P into the HSP27 containing band is indicated. In (F), cells were treated for 15 min with SB203580 (upper panel) or with PD098059 (lower panel) and then were exposed to VEGF (5 ng/ml for 5 min). Extracts were then prepared and ERK2 activity (upper panel) and MAPKAP kinase 2/3 (lower panel) activity assayed in immunocomplexes as in a and c. Representative results from two separate experiments are shown p38 MAP kinase regulates cell migration induced by VEGF S Rousseau et al cytoskeleton at concentrations that stimulate cell migration. Cells were exposed for various periods of time to 5 ng/ml VEGF, a concentration which maximally increased cell migration. After exposure, the cells were ®xed, stained for F-actin with FITCconjugated phalloidin and examined by confocal microscopy. In untreated HUVEC, F-actin was found mostly in cortical structures forming characteristic rues (Figure 6a ). VEGF produced a dramatic reorganization of F-actin characterized by the formation of long stress ®bers which traversed the cells and which were detected as early as after 10 min, reached a maximum by 15 min (Figure 6b ) and were still present after 2 h (data not shown). Stress ®ber formation was associated with the assembly of vinculin (Figures 6e and f) to focal adhesions. The role of the MAP kinases p38 and ERK in mediating the VEGF-induced stress ®ber accumulation and formation of focal adhesion was ascertained by examining the eect of SB203580 and PD098059 on the VEGF-induced stress ®ber formation in HUVEC. Cells were treated for 15 min with varying concentrations of SB203580 or with 25 mM PD098059 and then for 15 min with 5 ng/ml VEGF. After treatments, F-actin was stained and the cells were examined by confocal microscopy as above. Inhibition of ERK activation had no eect on the rearrangement of F-actin and the formation of focal adhesion induced by VEGF (Figures 6c and g ). However, pre-treatments of the cells with SB203580 inhibited, in a dose-dependent manner, both the formation of stress ®bers and the assembly of vinculin to focal adhesions. The inhibitory eect of SB203580 started at 0.5 mM and was maximal at 1 mM (Figures 6d and h) . Interestingly, the concentrations of SB203580 which inhibited stress ®ber accumulation and recruitment of vinculin into focal adhesions were the same which inhibited the p38-dependent-activation of MAPKAP kinase-2/3 ( Figure  4c ), phosphorylation of HSP27 (Figure 4e ) and cell migration (Figure 4d ). In the absence of VEGF, SB203580 had no eect on micro®laments organization and focal adhesions even at concentrations up to 25 mM (data not shown and Huot et al., 1997) . Since SB203580 inhibits the activity of p38 but has no eect on its activation (Young et al., 1997; Huot et al., 1997) , the results suggest that the micro®lament reorganization and assembly of focal adhesions triggered by VEGF are mediated by elements downstream of p38.
Discussion
In the present study, we showed for the ®rst time that VEGF activates the p38 MAP kinase pathway. The prompt activation of the p38 pathway by VEGF supports the emerging idea that p38 is not only activated by stress and cytokines, as initially suggested, but also by tyrosine kinase agonists and thus is involved in mediating their responses. VEGF uses two receptors, Flt-1 (VEGFR-1) and KDR/Flk-1 (VEGFR-2) that belong to the tyrosine kinase receptor family (Mustonen and Alitalo, 1995; Soker et al., 1996) . These two receptors mediate dierent cellular responses possibly by activating dierent intracellular signalling pathways (Breier and Risau, 1996) . The identi®cation of the molecular mechanisms connecting tyrosine kinase activation to p38 activation remains to be ascertained. The stimulation of p38 by VEGF is of great physiological signi®cance since we showed that the p38 MAP kinase pathway is an important component of the signalling network which transduces the migratory signals generated by VEGF suggesting that it may play an important role in regulating angiogenesis. We found, indeed, similar dose-response curves for VEGF-induced activation of p38 and cell migration, and for SB203580-induced inhibition of p38 activity and cell migration.
VEGF also induced in HUVEC a transient activation of ERK. However, inhibiting the VEGF- ]thymidine is ERK-but not p38-dependent. HUVEC were plated for 24 h in full medium and then for an additional 24 h in medium containing only 5% FBS in the absence of ECGS. In (A) cells were left untreated (ctl) or were treated with PD098059 (25 mM) or SB203580 (1 mM) added 15 min before VEGF (5 ng/ml). After 24 h, 1 mCi [ 3 H]thymidine was added and the cultures incubated for another 24 h. In (B) cells were left untreated (ctl) or were treated with PD098059 (25 mM) and incubated for 4 h in the presence of 1 mCi [ 3 H]thymidine. Acido-insoluble material was precipitated by 10% trichloroacetic acid. After washings, radioactivity incorporated into DNA was determined by liquid scintillation counting. Results represent the mean+s.d. of three separate dishes p38 MAP kinase regulates cell migration induced by VEGF S Rousseau et al induced activation of ERK with PD098059 did not inhibit cell migration indicating that the ERK pathway is not an obligatory regulator of cell migration. A similar conclusion was reached in NR6 cells where the capacity of mutant EGF receptors to mediate ERK activation does not correlate with their capacity to mediate cell movement (Chen et al., 1994) . It is more likely that ERK activation in endothelial cells rather regulates cell proliferation which is also a prerequisite to angiogenesis. Indeed, blocking ERK activation, but not blocking p38 activity, reduced the basal level of Induction of cell migration in response to motogenic factors such as VEGF is a tightly regulated process requiring the coordination of a complex set of inward and outward signals involving the extracellular matrix, the integrins and the actin cytoskeleton-associated motile apparatus (Nobes and Hall, 1995; Huttenlocher et al., 1995; Lauenburger and Horwitz, 1996; Mitchison and Cramer, 1996) . The importance of the actin cytoskeleton in cell migration is well accepted. In several cell lines such as bovine neutrophils exposed to chemotactic agents or keratinocytes exposed to hepatocyte growth factor, inhibiting RhoA-mediated stress ®ber and focal adhesion formation by C3 exotoxin or by microinjecting rhoGDI was found to inhibit cell motility (Stasia et al., 1991; Takaishi et al., 1994) . Similarly, we found that cytochalasin D, an inhibitor of actin polymerization and micro®lament formation, totally inhibited VEGFinduced cell migration (data not shown). VEGF in motogenic concentrations induced stress ®ber formation and recruitment of vinculin to focal adhesions in a pattern that is typical to migrating endothelial cells where well formed focal adhesions and stress ®bers aligned in the direction of migration were described (Madri et al., 1988; Romer et al., 1994) . Both stress ®ber and vinculin-containing focal adhesion formations were abrogated by SB203580 in concentrations which inhibited cell migration. In contrast, inhibiting ERK activation with PD098059 had no eect on the actin cytoskeleton reorganization induced by VEGF. All these results suggest that the cytoskeletal changes induced by VEGF are responsible for the motogenic eect of VEGF and that both events are mediated by activation of the p38 MAP kinase pathway. We previously demonstrated that activation of p38 also mediates actin ®lament Figure 6 p38-dependent stress ®ber formation induced by VEGF. HUVEC plated on gelatin-coated slides were left untreated (A and E) or were exposed for 15 min to 5 ng/ml VEGF (B and F) or pretreated for 15 min respectively with 25 mM PD098959 (C and G) or 1 mM SB203580 (D and H) and treated for 15 min with 5 ng/ml VEGF. F-actin (A, B, C, D) was detected using FITCconjugated phalloidin. Vinculin (E, F, G, H) was detected using the hVIN-1 monoclonal antibody and the vinculin antigen-antibody complexes were detected with biotin labeled anti-mouse IgG and were revealed with Texas-Red-conjugated streptavidin. Cells were examined by confocal microscopy. Rues are indicated by arrow. Representative ®elds are shown. Similar results were obtained in seven distinct experiments. Bar, 25 mm p38 MAP kinase regulates cell migration induced by VEGF S Rousseau et al reorganization in HUVEC in response to oxidative stress . It is plausible that several responses associated with actin ®lament dynamics in endothelial cells as well as in other cell types may be dependent on p38 activation. For example, p38 regulation of platelet aggregation by collagen may also be mediated by a p38-dependent actin reorganization (Saklatvala et al., 1996) . The mechanisms by which p38 modulates microfilament reorganization in response to VEGF remain to be ascertained. In many cellular systems, a major substrate of p38 is MAPKAP kinase 2/3, a serine threonine kinase for which a role in actin regulation has been suggested on the basis that two of its known substrates, LSP-1 and HSP27, are actin-binding proteins (Miron et al., 1991; Jongstra-Bilen et al., 1992; Huang et al., 1997) . Whereas LSP-1 expression is restricted to lymphoid and myeloid cells, HSP27 is a widely expressed protein (Huang et al., 1997; Arrigo and Landry, 1994) . In vitro, HSP27 acts as an F-actin cap binding protein whose activity is regulated by phosphorylation. Puri®ed unphosphorylated monomeric HSP27, but not phosphorylated HSP27, inhibits actin polymerization (Miron et al., 1991; Bendor et al., 1994) . Direct in vivo evidence for a role of HSP27 phosphorylation in regulating actin dynamics has been obtained. In ®broblasts, overexpression of HSP27 increases the stability of F-actin during incubation in presence of cytochalasin D, stabilizes Factin and enhances polymerization during oxidative shock, and enhances accumulation of F-actin in response to growth factors (Lavoie et al., 1993; Huot et al., 1996; Guay et al., 1997) . All these actin-modulatory eects of HSP27 require its phosphorylation since the phenotype is not observed in cells that overexpress a phosphorylation mutant of HSP27, or, if cells that overexpress wild type HSP27 are incubated in the presence of SB203580. The level of expression of HSP27 is particularly high in endothelial cells and we showed here that activation of p38 is essential for activation of MAPKAP kinase 2/3 and phosphorylation of HSP27 in response to VEGF. This suggests that HSP27 is a likely downstream eective target of p38 in the regulation of the VEGF-induced actin rearrangement and the resulting increased cell migration.
In summary, we have demonstrated that the p38 MAP kinase pathway is involved in modulating the migratory eects of VEGF in HUVEC and obtained evidence suggesting that this eect is regulated through a p38-mediated micro®lament rearrangement. The ®nding that p38 may regulate cell migration identi®es the p38 MAP kinase pathway as a new target to modulate cell motility and angiogenesis. In this context, inhibitors of this pathway, such as the pyridinyl imidazole derivatives, may have interesting therapeutic potential in controlling the deleterious neovascularization process associated with tumoral development.
Materials and methods
Materials
[g-32 P]ATP (3000 Ci/mmol) was purchased from Dupont Canada Inc. VEGF 165 , endothelial cell growth supplement (ECGS) and endotoxin-free cell culture tested bovine serum albumin (BSA) were from Sigma and IL-1b from Boehringer Mannheim. SB203580 was a gift from Smith Kline Beecham Pharmaceuticals. PD098059 was purchased from RBI. Chemicals for electrophoresis were purchased from Bio-Rad and Fisher.
Antibodies and peptides
Anti-GST-MAPKAP kinase-2/3 is a polyclonal antibody raised in rabbit after injection a glutathione S-transferase (GST) fusion protein containing the 223 C-terminal amino acids of Chinese hamster MAPKAP kinase-2 (Huot et al., 1995) . This antibody immunoprecipitates both the p45 and p54 isoforms of human MAPKAP kinase-2 one of which may correspond to MAPKAP-kinase-3 (Huot et al., 1995; McLaughlin et al., 1996) . Anti-ERK2 is a rabbit polyclonal antibody raised against a synthetic peptide corresponding to the 14 carboxy-terminal amino acids of rat ERK2 (Huot et al., 1995) . Anti-p38 is a polyclonal antibodies raised in rabbit against the C-terminal sequence PPLQEEMES of murine p38 (Guay et al., 1997; Huot et al., 1997) . hVIN-1 is an anti-human vinculin monoclonal antibody purchased from Sigma.
Cells
HUVEC were isolated by collagenase, digestion of umbilical veins from undamaged sections of fresh cords (Marceau et al., 1992; Huot et al., 1997) . The umbilical vein was cannulated, washed with Earle's basic salt solution (EBSS) and perfused for 10 min with collagenase (1 mg/ml) in EBSS at 378C. After perfusion, the detached cells were collected, the vein was washed with 199 medium and the wash-o pooled with the perfusate. After washing, cells were plated on gelatin coated 75 cm 2 culture dishes in 199 medium containing 20% heat-inactivated fetal bovine serum (FBS), ECGS (60 mg/ml), glutamine, heparin and antibiotics. Subcultures were obtained by trypsination and were used at passages 55. For kinase assays, HUVEC were incubated for 16 ± 24 h in ECGS-free medium containing 5% FBS before addition of VEGF. The identity of HUVEC as endothelial cells were con®rmed by their polygonal shape and by detecting their immunoreactivity for factor VIII related antigens. Cultures were incubated at 378C in a humidi®ed atmosphere containing 5% CO 2 .
Immunoprecipitation
After stimulation, cells were scraped and extracted in lysis buer containing 20 mM morpholino-propane-sulfonic acid (MOPS) pH 7.0, 10% glycerol, 80 mM b-glycerophosphate, 5 mM EGTA, 0.5 mM EDTA, 1 mM Na 3 VO 4 , 5 mM Na 4 P 2 O 7 , 50 mM NaF, 1% Triton X-100, 1 mM benzamidine, 1 mM dithiothreitol (DTT) and 1 mM phenylmethylsulfonyl¯uoride (PMSF). Extracts were vortexed and centrifuged at 17 000 g for 12 min at 48C. Clari®ed supernatants were immediately used for immunoprecipitation or were stored at 7808C. The further steps were done at 48C. Clari®ed supernatant was diluted four times in buer I (20 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.1 mM EDTA, 1 mM EGTA, 1 mM MgCl 2 , 1 mM Na 3 VO 4 , 1% Triton, 1 mM PMSF). Undiluted anti-p38, anti-ERK2 or anti-MAPKAP kinase 2/3 antibodies were added in limiting concentrations and the mixtures were incubated for 1 h. Ten to 15 ml of protein A Sepharose (Pharmacia) 50% v/v in buer I were added and the mixtures incubated for 30 min. Samples were centrifuged for 15 s and washed 3 times with 300 ml of buer I. Immunoprecipitates were directly used for kinase assays.
Kinase assays
MAPKAP kinase-2/3, ERK2 and p38 activities were assayed in immune complexes using appropriate subp38 MAP kinase regulates cell migration induced by VEGF S Rousseau et al strates. MAPKAP kinase-2/3 activity was assayed using recombinant HSP27 as substrate (Huot et al., 1995) . The assays were done in 25 ml of kinase buer K: 100 mM ATP, 3 mCi of [g 32 P]ATP (3000 Ci/mmole), 40 mM pnitrophenyl phosphate, 20 mM MOPS pH 7.0, 10% glycerol, 15 mM MgCl 2 , 0.05% Triton X-100, 1 mM DTT, 1 mM leupeptin, 0.1 mM PMSF and 0.3 mg of protein kinase A inhibitor. The kinase activity was assayed for 30 min at 308C and was stopped by adding. 10 ml SDS ± PAGE loading buer. Immunoprecipitated ERK2 and p38 were assayed analogously using respectively myelin basic protein (MBP) and ATF2-GST as substrates (DeÂ rijard et al., 1995) . Kinase assay buer K containing 10 mM MgCl 2 was used for ERK2. Assay medium for p38 contained 50 mM HEPES pH 7.4, 50 mM b-glycerophosphate, 50 mM MgCl 2 , 0.2 mM Na 3 VO 4 , 4 mM DTT, ATF2-GST and [g-32 P]ATP (3000 Ci/mmol). In the case of SAPK1/JNK activity, the cell extract was adsorbed on GST-Jun beads and the kinase tested using the same GST-N terminal Jun as substrate (Kyriakis et al., 1994) . Brie¯y, the GST-Jun fusion proteins bound to glutathione Sepharose beads were incubated for 30 min at 48C with the extracts in buer I. The beads were then pelleted, washed with I buer and incubated for 30 min at 378C with 3 mCi [g-32 P]ATP (3000 Ci/mmol) in buer K containing 10 mM MgCl 2 . The phosphorylated GST-Jun was boiled in SDS sample buer to stop the reaction. The activity of the various kinases were quanti®ed by measuring the incorporation of radioactivity into the speci®c substrate after SDS ± PAGE.
In vivo phosphorylation
Phosphorylation of HSP27 was evaluated by labelling with H 3 [ 32 P]O 4 as reported . Cells were preincubated for 2 h in phosphate-free medium containing 25 mCi/ml H 3 [ 32 P]O 4 (900 ± 1100 mCi/mmol) and then were left untreated or treated as indicated. Immediately after treatments, the cells were lysed and proteins were fractionated by SDS ± PAGE. The radioactivity incorporated in HSP27 was evaluated by autoradiography.
Cell migration assay
Cell migration was assayed using a modi®ed Boyden chamber assay as described previously (Kundra et al., 1995; Kuzuya and Kinsella, 1994) . Brie¯y, exponentially growing cells were harvested with trypsin, counted, centrifuged and resuspended at 0.5 or 1.5610 6 cells/ml in migration buer (199 medium, 10 mM HEPES pH 7.4, 1.0 mM MgCl 2 , 0.5% BSA). Cells were then added on a 8.0 mm pore size gelatinized polycarbonate membrane separating the two chambers of a 6.5 mm transwell (Costar). After one hour of adhesion, either 1% BSA, as a negative control (upper and lower chamber), or VEGF (lower chamber) were added. When indicated, SB203580, PD098059 or the vehicle (0.25% DMSO), previously diluted in migration buer, were added to both chambers 15 min before VEGF. After 2 h cells on the upper face of the membrane were scraped using a cotton swab and cells on the lower face ®xed with 3.7% formaldehyde and stained with Mayer's Hematoxylin solution. The number of migrated cells on the lower face of the ®lter was counted in ®ve ®elds under a 6100 magni®cation. Assays were done in triplicate and repeated at least twice.
Incorporation of thymidine into DNA
Cells were incubated for 24 h in full 199 medium containing 20% FBS and ECGS (60 mg/ml) and then were made quiescent by a 24 h incubation in medium supplemented with only 5% FBS in the absence of ECGS. VEGF was then added for 24 h in presence or not of SB203580 or PD098059. Thereafter, 1.0 mCi [ 3 H]thymidine (Amersham) was added for another 24 h in the presence of the various treatments (Narioka et al., 1987; LeÂ vesques et al., 1995) . In some experiments quiescent cells, were left untreated or were treated with PD098059 and incubated for 4 h in the presence of 1 mCi [ 3 H]thymidine. [ 3 H]thymidine incorporated into DNA was determined by adding 10% trichloroacetic acid (TCA) to the cultures maintained on ice. The cells were then rinsed twice with cold TCA and the precipitates solubilized in 0.1 N NaOH and neutralized with 0.1 N HCl. Incorporation of [ 3 H]thymidine was determined by liquid scintillation counting.
Confocal¯uorescence microscopy F-actin detection was done as previously reported . HUVEC were plated on gelatin-coated slides. They were then ®xed with 3.7% formaldehyde and permeabilized with 0.1% saponin in phosphate buered saline, pH 7.5. F-actin was detected using FITC-conjugated phalloidin (33.3 mg/ml) diluted 1:50 in phosphate buer. Vinculin was detected using the hVIN-1 monoclonal antibody. Vinculin antigen-antibody complexes were visualized with biotin-labeled anti-mouse IgG and were revealed with Texas Red-conjugated streptavidin. Cells were examined by confocal microscopy with a Bio-Rad MRC-600 imaging system mounted on a Nikon Diaphot-TDM equipped with a 606 objective lens with a 1.4 numerical aperture .
